Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeCost of RevenueEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)
Others
Ratios

Whitehawk Therapeutics (WHWK) Interest Expenses (2020 - 2024)

Historic Interest Expenses for Whitehawk Therapeutics (WHWK) over the last 5 years, with Q3 2024 value amounting to $38000.0.

  • Whitehawk Therapeutics' Interest Expenses fell 3448.28% to $38000.0 in Q3 2024 from the same period last year, while for Jun 2025 it was $38000.0, marking a year-over-year decrease of 8354.98%. This contributed to the annual value of $154000.0 for FY2024, which is 3333.33% down from last year.
  • According to the latest figures from Q3 2024, Whitehawk Therapeutics' Interest Expenses is $38000.0, which was down 3448.28% from $58000.0 recorded in Q2 2024.
  • Whitehawk Therapeutics' Interest Expenses' 5-year high stood at $229000.0 during Q3 2020, with a 5-year trough of $38000.0 in Q3 2024.
  • For the 5-year period, Whitehawk Therapeutics' Interest Expenses averaged around $94375.0, with its median value being $58000.0 (2022).
  • Examining YoY changes over the last 5 years, Whitehawk Therapeutics' Interest Expenses showed a top increase of 0.0% in 2022 and a maximum decrease of 7444.93% in 2022.
  • Over the past 5 years, Whitehawk Therapeutics' Interest Expenses (Quarter) stood at $229000.0 in 2020, then plummeted by 75.11% to $57000.0 in 2021, then changed by 0.0% to $57000.0 in 2022, then changed by 0.0% to $57000.0 in 2023, then crashed by 33.33% to $38000.0 in 2024.
  • Its Interest Expenses stands at $38000.0 for Q3 2024, versus $58000.0 for Q2 2024 and $58000.0 for Q1 2024.